title: Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis.
authors.affiliation: Service of Neurology, Rehabilitation Center, Brissago, Switzerland. thierry.kuntzer@chuv.ch
authors.forename: T
authors.initials: T
authors.lastname: Kuntzer
authors.forename: A
authors.initials: A
authors.lastname: Carota
authors.forename: J
authors.initials: J
authors.lastname: Novy
authors.forename: M
authors.initials: M
authors.lastname: Cavassini
authors.forename: R A
authors.initials: RA
authors.lastname: Du Pasquier
mesh_terms: D000906:Antibodies / Q000097:blood; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D005260:Female; D006679:HIV Seropositivity / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D009157:Myasthenia Gravis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D020794:Receptor Protein-Tyrosine Kinases / Q000276:immunology; D011950:Receptors, Cholinergic / Q000276:immunology; D000069283:Rituximab; D055815:Young Adult
chemical_list: D000906:Antibodies; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D011950:Receptors, Cholinergic; D000069283:Rituximab; C095714:MUSK protein, human; D020794:Receptor Protein-Tyrosine Kinases